Certican®

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Renal Interstitial FibrosisRenal Transplantation

Phase 2

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

CompletedNCT01596062

Novartis PharmaceuticalsRenal Transplantation

Start: 2012-03-31End: 2013-03-31Updated: 2014-07-25

Phase 3

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

CompletedNCT01079143

Novartis PharmaceuticalsRenal Interstitial Fibrosis

Start: 2009-09-30End: 2012-06-30Updated: 2014-03-18

Related Papers

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study

BMJ Open2021-10-0140 citations

Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study

BMJ2019-09-17310 citations

CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen

Transplant International2015-09-157 citations